肺腺癌患者化疗前后血清可溶性Fas检测的临床意义  

Clinical significance of levels of serum soluble Fas before and after chemotherapy in patients with lung adenocarcinoma

作　　者：陈小兵[1] 肖毅军[1] 罗素霞[1] 

机构地区：[1]河南省肿瘤医院内科,河南郑州450008

出　　处：《中国肿瘤临床与康复》2006年第4期292-294,共3页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：河南省科委2004科技攻关基金资助项目(0523030300)

摘　　要：目的检测肺腺癌患者化疗前后血清可溶性Fas(sFas)水平并探讨其临床意义。方法应用酶联免疫吸附试验法(ELISA)检测60例肺腺癌患者化疗前后血清sFas水平,并同时检测30例正常人血清sFas水平作对比分析。结果肺腺癌患者血清sFas水平明显高于正常对照组(P<0.01)。血清sFas水平与临床分期有关,与肺腺癌患者性别、年龄、细胞分化程度无关。Ⅳ期肺腺癌血清sFas水平明显高于Ⅲ期和Ⅱ期(P<0.01),Ⅲ期明显高于Ⅱ期(P<0.01)。化疗后有效(完全缓解和部分缓解)患者血清sFas水平明显低于化疗前(P<0.01)。结论血清sFas与肺腺癌的发生及发展有一定关系,检测血清sFas有可能成为肺腺癌辅助诊断、病情发展及化疗疗效观察的一项有价值的指标。Objective To analyse the levels of soluble Fas（sFas） before and after chemotherapy with vinorelbine combined with cisplatin in patients with lung adenocareinoma and its clinical significance. Methods Enzyme linked immunosorbent assay （ELISA） was used to measure the levels of sFas in 60 patients with lung adenocarcinoma before and after chemotherapy and 30 healthy persons used as normal control subjects. Results Levels of sFas were elevated in patients with lung adenocarcinoma before and after chemotherapy as compared with the control group（P 〈 0.01 ）. The level of sFas was correlated with clinical stage, but not with sex,age and histological grade. The sFas level in stage Ⅳ was higher than that in stages Ⅲ　and Ⅱ（P〈0.01） ,and that in stage Ⅲ was higher than that in stage Ⅱ（P〈0.01）. It was remarkably reduced in complete remission or partial remission periods after chemotherapy （ P 〈 0.01 ）. Conclusion The elevation of sFas was correlated with progression for lung adenocarcinoma and it may be used as a criterion for the diagnosis and the progress of the disease as well as for evaluating the curative effects of chemotherapy in pa- tients with lung adenocarcinoma.

关 键 词：肺肿瘤/化学疗法 可溶性FAS 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]